1.76
1.73%
0.03
Handel nachbörslich:
1.79
0.03
+1.70%
Schlusskurs vom Vortag:
$1.73
Offen:
$1.75
24-Stunden-Volumen:
3.39M
Relative Volume:
6.79
Marktkapitalisierung:
$117.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.36M
KGV:
-0.4005
EPS:
-4.394
Netto-Cashflow:
$-15.05M
1W Leistung:
+2.33%
1M Leistung:
-30.98%
6M Leistung:
-52.82%
1J Leistung:
-44.65%
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Vergleichen Sie ZURA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.76 | 117.20M | 0 | -60.36M | -15.05M | -4.394 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-04 | Eingeleitet | Leerink Partners | Outperform |
2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
2024-05-03 | Eingeleitet | Piper Sandler | Overweight |
2023-10-10 | Eingeleitet | Ladenburg Thalmann | Buy |
2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
2023-06-22 | Eingeleitet | Guggenheim | Buy |
2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN
Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance
Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada
Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com
Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St
Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Zura Bio shares outlook positive as Phase 2 TibuSURE study evaluates key SSc complications - Investing.com India
Zura Bio begins Phase 2 study for systemic sclerosis treatment By Investing.com - Investing.com South Africa
Zura Bio initiates Phase II systemic sclerosis treatment trial - Yahoo Finance
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Quantisnow
17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company - Defense World
Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Analysts - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average Target Price from Analysts - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Update - Defense World
Zura Bio : to Present at the Piper Sandler 36th Annual Healthcare Conference Form 8 K - Marketscreener.com
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Zura Bio to Present at Piper Sandler Healthcare Conference, Showcasing Immunology Pipeline - StockTitan
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - Simply Wall St
HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA) - Defense World
HC Wainwright Reaffirms "Neutral" Rating for Zura Bio (NASDAQ:ZURA) - MarketBeat
GREAT POINT PARTNERS LLC Reduces Stake in Zura Bio Ltd - GuruFocus.com
ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd - GuruFocus.com
Zura Bio advances Phase 2 study for systemic sclerosis treatment - Investing.com
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis - Yahoo Finance
HC Wainwright Has Positive Outlook for Zura Bio Q3 Earnings - MarketBeat
Guggenheim maintains Buy on Zura Bio, target steady at $15 - Investing.com India
Guggenheim maintains Buy on Zura Bio, target steady at $15 By Investing.com - Investing.com UK
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - BioSpace
Q3 Earnings Forecast for Zura Bio Issued By Leerink Partnrs - MarketBeat
Zura Bio (NASDAQ:ZURA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com
Leerink Partners initiates Zura Bio stock with Outperform rating, $15 target - Investing.com
Zura Bio Ltd re-elects board, ratifies auditor at AGM By Investing.com - Investing.com Australia
Zura Bio to Participate in Two Upcoming Investor Conferences in November - Yahoo Finance
Zura Bio Ltd re-elects board, ratifies auditor at AGM - Investing.com India
Zura Bio announces departure of Chief Scientific Officer By Investing.com - Investing.com Australia
Zura Bio announces departure of Chief Scientific Officer - Investing.com India
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):